In the present study we investigated the clinical and immunological evaluation of inclusion into medical complex in phlegmon of the maxillofacial region leukinferon immunomodulatory drug. The study included 100 patients with phlegmon of the maxillofacial region, randomized into 2 groups: I group consisted of 50 people who received conventional treatment; II group consisted of 50 people, in a comprehensive treatment that was included leukinferon. The data on the marked immunomodulatory effect on neutrophil granulocytes leukinferon system, as well as cell-mediated immunity. These effects provide a rapid withdrawal of patients from the state of secondary immune deficiency. Clinically, patients of group II marked a more effective relief of endogenous intoxication, shortening wound cleansing, shortening imposition of secondary sutures and overall duration of treatment in the hospital compared with patients in group I
